Cargando…
A thioredoxin reductase inhibitor ethaselen induces growth inhibition and apoptosis in gastric cancer
Gastric cancer (GC) is the third leading cause of cancer deaths worldwide. Conventional chemotherapy has been proven useful to only a portion of the patients. Previous developed targeted drugs are more effective and tolerable than conventional drugs. Thus the development of novel drugs targeting mar...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086267/ https://www.ncbi.nlm.nih.gov/pubmed/32226516 http://dx.doi.org/10.7150/jca.40744 |
_version_ | 1783509092387520512 |
---|---|
author | Wu, Wang Yang, Zhiying Xiao, Xing An, Tailai Li, Bo Ouyang, Jun Li, Huafu Wang, Chunming Zhang, Yawei Zhang, Haiyong He, Yulong Zhang, Changhua |
author_facet | Wu, Wang Yang, Zhiying Xiao, Xing An, Tailai Li, Bo Ouyang, Jun Li, Huafu Wang, Chunming Zhang, Yawei Zhang, Haiyong He, Yulong Zhang, Changhua |
author_sort | Wu, Wang |
collection | PubMed |
description | Gastric cancer (GC) is the third leading cause of cancer deaths worldwide. Conventional chemotherapy has been proven useful to only a portion of the patients. Previous developed targeted drugs are more effective and tolerable than conventional drugs. Thus the development of novel drugs targeting markers is an urgent task and the main direction for future research. Ethaselen, an inhibitor of thioredoxin reductase (TrxR), has been considered an important anticancer target drug. Previous studies show that it is effective on treating many kinds of cancers. In this paper, we examined that ethaselen effectively inhibited the growth of gastric cancer cells and promoted apoptosis. Organoids were cultured from patient-derived cells in a three-dimension form which are widely used in cancer research to help us understand cancer cells behavior at the sub-organ level and develop novel drugs. We established a drug testing and screening system using GC-derived organoids by recapitulating tumor microenvironment. We confirmed that the TrxR-targeting ethaselen could be a novel and effective drug for gastric cancer treatment. |
format | Online Article Text |
id | pubmed-7086267 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-70862672020-03-27 A thioredoxin reductase inhibitor ethaselen induces growth inhibition and apoptosis in gastric cancer Wu, Wang Yang, Zhiying Xiao, Xing An, Tailai Li, Bo Ouyang, Jun Li, Huafu Wang, Chunming Zhang, Yawei Zhang, Haiyong He, Yulong Zhang, Changhua J Cancer Research Paper Gastric cancer (GC) is the third leading cause of cancer deaths worldwide. Conventional chemotherapy has been proven useful to only a portion of the patients. Previous developed targeted drugs are more effective and tolerable than conventional drugs. Thus the development of novel drugs targeting markers is an urgent task and the main direction for future research. Ethaselen, an inhibitor of thioredoxin reductase (TrxR), has been considered an important anticancer target drug. Previous studies show that it is effective on treating many kinds of cancers. In this paper, we examined that ethaselen effectively inhibited the growth of gastric cancer cells and promoted apoptosis. Organoids were cultured from patient-derived cells in a three-dimension form which are widely used in cancer research to help us understand cancer cells behavior at the sub-organ level and develop novel drugs. We established a drug testing and screening system using GC-derived organoids by recapitulating tumor microenvironment. We confirmed that the TrxR-targeting ethaselen could be a novel and effective drug for gastric cancer treatment. Ivyspring International Publisher 2020-03-04 /pmc/articles/PMC7086267/ /pubmed/32226516 http://dx.doi.org/10.7150/jca.40744 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Wu, Wang Yang, Zhiying Xiao, Xing An, Tailai Li, Bo Ouyang, Jun Li, Huafu Wang, Chunming Zhang, Yawei Zhang, Haiyong He, Yulong Zhang, Changhua A thioredoxin reductase inhibitor ethaselen induces growth inhibition and apoptosis in gastric cancer |
title | A thioredoxin reductase inhibitor ethaselen induces growth inhibition and apoptosis in gastric cancer |
title_full | A thioredoxin reductase inhibitor ethaselen induces growth inhibition and apoptosis in gastric cancer |
title_fullStr | A thioredoxin reductase inhibitor ethaselen induces growth inhibition and apoptosis in gastric cancer |
title_full_unstemmed | A thioredoxin reductase inhibitor ethaselen induces growth inhibition and apoptosis in gastric cancer |
title_short | A thioredoxin reductase inhibitor ethaselen induces growth inhibition and apoptosis in gastric cancer |
title_sort | thioredoxin reductase inhibitor ethaselen induces growth inhibition and apoptosis in gastric cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086267/ https://www.ncbi.nlm.nih.gov/pubmed/32226516 http://dx.doi.org/10.7150/jca.40744 |
work_keys_str_mv | AT wuwang athioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT yangzhiying athioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT xiaoxing athioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT antailai athioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT libo athioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT ouyangjun athioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT lihuafu athioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT wangchunming athioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT zhangyawei athioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT zhanghaiyong athioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT heyulong athioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT zhangchanghua athioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT wuwang thioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT yangzhiying thioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT xiaoxing thioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT antailai thioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT libo thioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT ouyangjun thioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT lihuafu thioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT wangchunming thioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT zhangyawei thioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT zhanghaiyong thioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT heyulong thioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer AT zhangchanghua thioredoxinreductaseinhibitorethaseleninducesgrowthinhibitionandapoptosisingastriccancer |